Azelastine - NDSRI's
References
FAQ's
References
- Engel, Juergen; Scheffler, Gerhard, 4-Benzyl-1-2(H)-Phthalazinone Derivatives, Asta-Werke A.-G., Federal Republic of Germany, EP222191B1, January 30, 1991
- Pivonka, J.; Segelman, F. H.; Hartman, C. A.; Segl, W. E.; Kucharczyk, N.; Sofia, R. D., Determination of azelastine and desmethylazelastine in human plasma by high-performance liquid chromatography, Journal of Chromatography, Biomedical Applications, Volume: 420, Issue: 1, Pages: 89-98, 1987
Frequently Asked Questions
Can Azelastine impurities affect the drug's bioavailability?
Impurities in Azelastine can affect the drug's bioavailability and its therapeutic effect.
How are the impurities in Azelastine controlled during manufacturing?
Impurities in Azelastine are controlled during manufacturing through various methods, such as monitoring and controlling the manufacturing process, testing at different stages of production, and using validated analytical methods.
What are the sources of Azelastine impurities?
Impurities in Azelastine can come from the starting materials, intermediates, degradation products, or residual solvents used in the manufacturing process.
What are the temperature conditions required to store Azelastine impurities?
Azelastine impurities are stored at a controlled room temperature between 2-8 °C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.